Skip to main content

Abstract

Background and Purpose— In the concept of ischemic penumbra, the volume of salvaged penumbra is considered as the volume of FLAIR normalization on follow-up MRI compared with early diffusion and perfusion abnormalities. Using magnetization transfer imaging, very sensitive to macromolecular disruption, we investigated whether FLAIR normalization was a good marker for tissue full recovery.
Methods— We prospectively included 30 patients with acute middle cerebral artery stroke. Diffusion-weighted imaging (DWI) and perfusion-weighted imaging were performed within 12 hours after onset (MRI.1), and the final infarct was documented by MRI with FLAIR and magnetization transfer at 1-month follow-up (MRI.2). We compared magnetic transfer ratio of a normal region with values measured at 1 month (MRI.2) in 4 regions of interest: (1) the initial DWI hypersignal (CORE=DWI_MRI.1); (2) the infarct growth area (infarct growth=FLAIR_MRI.2−DWI_MRI.1); (3) the hypoperfused area that normalized (reversible perfusion abnormalities=perfusion-weighted imaging_MRI.1−FLAIR_ MRI.2); and (4) the early DWI abnormalities that normalized (reversible diffusion abnormalities=DWI_MRI.1− FLAIR_MRI.2).
Results— In comparison with values obtained in normal tissue (magnetic transfer ratio=49.8%, SD=1.9), magnetic transfer ratio at 1 month was significantly decreased in reversible perfusion abnormalities (45.2%, SD=2.5; P<0.0001) and reversible diffusion abnormalities (43.2%, SD=2.8; P=0.0156). It was also markedly reduced, as expected, in the CORE (40.9%, SD=5.2) and infarct growth regions (43.1%, SD=2.0).
Conclusions— Magnetic transfer ratio assessed presence of microstructural damages in the MRI-defined salvaged penumbra. This may imply cellular loss and partial infarction. Evaluation of the efficacy of therapies that promote reperfusion or neuroprotection may benefit from this additional information.
Ischemic penumbra has been defined as tissue hypoperfused that is at risk for infarction but still salvageable. It is distinguished from the ischemic core, the tissue that is already irreversibly injured even if blood flow is re-established.1 It is a region of intense interest2,3 because it is the target of recanalization or neuroprotective therapies and the volume of salvaged penumbra calculated on MRI has become one criteria to evaluate the efficacy of thrombolytics and neuroprotective drugs.
MRI can identify the ischemic penumbra with the concept of perfusion/diffusion mismatch.1,4 The region with perfusion abnormalities and normal diffusion imaging (“mismatch”) identifies tissue that is hypoperfused but has not yet experienced advanced bioenergetic failure and represents the penumbra. This simple model is nevertheless only a rough approximation of the ischemic penumbra. Notably, recent publications suggest that diffusion abnormalities overestimate irreversible damage,5,6 with many reports of final infarct volume smaller than the initial diffusion hyperintensity.7–9 On the basis of these findings, penumbra includes not only diffusion/perfusion mismatch but also portions of the initial diffusion abnormality itself.1 Therefore, the volume of salvaged penumbra is considered as the volume of perfusion or even diffusion abnormalities seen on early MRI studies, and normalized on T2 or FLAIR-weighted images obtained at follow-up MRI.
However, such follow-up images only identify gross anatomical changes of cerebral tissue after an acute ischemic event but are not sensitive enough to investigate the microstructural changes present in the “normal” brain tissue located around the final infarct core, ie, in the previous ischemic penumbra. Such abnormalities could be investigated using magnetization transfer (MT) imaging. From this MRI sequence, numeric data called MT ratio (MTR) are calculated pixel by pixel and represented as a color-coded map.10 MTR gives an indication of the quantity of bound protons present in the tissue, and these are mostly located in the cholesterol-containing membrane lipid bilayer of cells.11 Therefore, MTR provides information proportional to the macromolecular content that are different from conventional parameters such as T2. Furthermore, MTR depicts microstructural damage whereas the same region could appear normal using T2.12 It is a very robust sequence widely validated, with histological correlations in human and animal studies in multiple sclerosis and several others conditions.13
We hypothesized that ischemic damages could be present in an at-risk region that appears “normal” on follow-up FLAIR imaging and we used MTR as a marker to investigate damage in this “reperfused penumbra”.

Subjects and Methods

Patients

The 30 patients prospectively included in this study were initially admitted to the emergency neurological ward of the University Hospital Pellegrin, Bordeaux, for a suspected cerebral infarct.
Primary inclusion criteria were as follows: men and women, older than 18 years, with a clinical diagnosis of moderate to severe cerebral infarct (NIHSS between 4 and 20) in the left or right middle cerebral artery territory evolving for <12 hours. Noninclusion criteria were: coma, transient ischemic attacks or lacunar syndrome, pregnant or breast-feeding women or women without a negative pregnancy test, and contraindications to MRI. Written informed consent was obtained from all participants. The study was part of an approved national Research and Clinical Hospital Project called VIRAGE (VIRAGE for “Valeur predictive des parametres IRM à la phase aigue de l’accident vasculaire cerebral: application à la gestion des essais thérapeutiques”). It was approved by the local research ethics committee.

MRI Protocol

Using VIRAGE data, 2 MRI studies were analyzed. The first was performed within 12 hours after the occurrence of stroke symptoms (MRI.1) and the second was performed between days 30 and 45 after the first (MRI.2). The NIHSS was assessed before MRI.1 and Barthel Index and Rankin modified scale before MRI.2. All data were reported on a standardized case report form.
MRI studies were performed on a 1.5-T magnet (Philips Gyroscan; Philips Medical System). MRI.1 protocol included diffusion-weighted images (DWI) and bolus tracking perfusion-weighted images (PWI). MRI.2 included a FLAIR and MT sequences. A 3-dimensional T1 was performed in both MRI studies to allow coregistration. All images were acquired in the anterior commissure–posterior commissure plane.
DWI were performed with a single-shot spin echo planar imaging sequence using the following parameters: 24 slices; slice thickness, 5 mm; TR/TE, 6000 ms/114 ms; matrix, 128×128; and field of view, 240 mm. Gradients with 2 different b values (0 and 1000 s/mm2) in the x, y, and z axes were used.
PWI were acquired by using the dynamic first-pass bolus tracking method and a single-shot echo planar imaging sequence: 24 slices 40 times every 2 seconds; slice thickness, 5 mm; TR/TE/α, 2000 ms/30 ms/45°; matrix, 128×128; and field of view, 240 mm. At the time of the fourth cycle of 24 slices, a dose of 0.1 mmol/kg Gd-DOTA was injected at a rate of 10 mL/s into a peripheral vein through an 18-gauge catheter by using a magnetic resonance-compatible power injector followed by a 10-mL saline flush at 5 mL/s.
For FLAIR sequences we used: 24 slices; thickness, 5 mm; TR/TE/TI, 10 000 ms/110 ms/2380 ms; matrix, 256×256; and field of view, 240 mm.
MT studies were obtained with a gradient echo imaging sequence with (Ms) and without (M0) a saturating pulse (bandwidth of 250 Hz): 24 slices; thickness, 5 mm; TR/TE/α, 35 ms/2.3 ms/8°; matrix, 256×256; and field of view, 240 mm. Sinc-shaped radio frequency pulse of 15 ms duration with a flip angle of 520° and an off-resonance frequency of 1500 Hz were used to get the MT effect.
The 3-dimensional T1 parameters were as follows: 80 slices; thickness, 3.4 mm with a slice gap of −1.7 mm; TR/TE/α, 20 ms/3 ms/30°; matrix, 256×256; and field of view, 240 mm.

Data Processing

Maps

By averaging the images obtained with the 3 diffusion weighting directions (b value of 1000 s/mm2), trace diffusion-weighted images were generated for each section.
Concerning PWI, time to peak (TTP) was the only parameter used in this study and refers to the time between the first imaging and the time at which the signal intensity reaches its minimum. A relative TTP delay superior to 4 seconds was chosen to define the area of perfusion abnormalities. This was chosen according to the literature indicating that this delay best identifies penumbral flow.14 Other parameter maps (relative cerebral blood volume and relative cerebral blood flow) were routinely calculated but not used in this study because the volume of the perfusion impairment was usually considerably more difficult to delineate on these maps than on the TTP one.3
MTR maps were calculated on a pixel-by-pixel basis using the following equation12: equation
Where M0 and Ms represent the signal intensity with the saturation prepulse off and on, respectively. MTR represented the percentage of signal loss after the saturation pulse and is proportional to the bound proton pools.10

Coregistration

All MRI sequences have been spatially registered using a fully automated 3-dimensional registration algorithm (Theralys). It used mutual information as a similarity measure to assess the goodness of match between the reference volume and the source volume. A rigid 3-dimensional registration was used. According to mutual information and mutual information derivative values, a gradient descent technique was used to iteratively modify the transformation parameters (rotations and translations) to maximize the mutual information.
A multi-resolution, coarse-to-fine strategy was adopted. That is to say, registration started at low resolution and once the convergence is reached, a new iteration is initialized based on the result of the previous step. Such a strategy increases the robustness of the registration algorithm. Results have been quality controlled for each and every processed MRI sequence to detect potential misregistration that may occur for echo planar imaging-based sequences for which geometric distortion may disturb the registration process. In a few cases, the sequence was manually registered to ensure good spatial correspondence.

Regions of Interest

Images were sent to a workstation using customized software developed by Theralys in which one observer visualized for each patient on the same screen: DWI_MRI.1, PWI_MRI.1, FLAIR_ MRI.1, and FLAIR_MRI.2. The 3-dimensional volumes were measured by manual contouring on each slice:
1.
The abnormal bright area on the initial DWI at b=1000 s/mm2: DWI_MRI.1.
2.
The area with a prolonged TTP >4 seconds on the initial TTP map: PWI_MRI.1.
3.
The bright area on the follow-up FLAIR images: FLAIR_MRI.2, which defined the final infarct volume. Enlarged sulci were included on FLAIR_MRI.2 when comparison with early MRI allowed the conclusion of atrophy. This was performed to avoid underestimation of the final infarct size attributable to the shrinking phenomenon.
We defined 4 types of pathophysiological regions of interest (ROI) derived from these initial 3 sets of volumes:
1.
The infarct CORE, defined as DWI_MRI.1.
2.
The infarct growth (IG), defined as [FLAIR_MRI.2]−[DWI_MRI.1] (Figure 1A).
   Figure 1. Illustration of ROI definition in 3 different patients. For each patient early DWI and PWI (MRI.1) and follow-up FLAIR and MTR (MRI.2) are shown. DWI area abnormality was propagated in follow-up MTR and represented with a blue contour. Abnormal FLAIR and TTP area were propagated using red and black contours, respectively. For patient A, MRI.1 was performed 4 hours and 5 minutes after stroke onset. NIHSS was scored at 4 points and Rankin at 1/5. DWI_MRI.1=28.5 cm3 and FLAIR_MRI.2=46.0 cm3. Mean MTR in this IG (red area) was 40.4% against 47.3% in mirror ROI. There was no RPA. For patient B, delay was 7 hours. NIHSS=15 and Rankin=2/5. There was an infarct growth of 13.2 cm3 for DWI through 20.0 cm3 for FLAIR (area not shown). A large RPA was evaluated at 47.9 cm3 (black area) with a mean MTR=40.0% against 45.0% in mirror ROI. For patient C, delay was 4 hours and 20 minutes. NIHSS=13 and Rankin=2/5. There was a 16.6 cm3 RDA (blue area) with a MTR measured at 39.2%. It coexisted with a 40.6 cm3 RPA (black area) with a mean MTR of 40.0% against 45.0% in mirror ROI.
3.
The reversible diffusion abnormalities (RDAs), defined when the final infarct on FLAIR was less important than the initial DWI volume as [DWI_MRI.1]−[FLAIR_MRI.2], which represented the initial DWI abnormality area that normalized (Figure 1C).
4.
The reversible perfusion abnormalities (RPA), defined as [PWI_MRI.1]−[FLAIR_MRI.2], which represented the initial hypoperfused area that normalized (Figure 1B). In the cases in which RPA coexists with RDA in a same patient, RPA was calculated as [PWI_MRI.1]−[DWI_MRI.1] so that RPA volume did not include RDA (Figure 1C).
The CORE, IG, RPA, and RDA volumes were calculated as the sum of the area of the ROIs on each slice multiplied by the slice thickness plus the interslice gap.
FLAIR_MRI.2 volume was mirrored to the unaffected hemisphere and adjusted to avoid focal contralateral hyperintensity. This normal contralateral mirror region was used as a control ROI for each patient.

MTR Quantitative Measurements

CORE, IG, RDA, RPA, and mirror ROIs were automatically propagated on the final MT sequence obtained on MRI.2. This allowed generating MT histogram parameters in these different ROIs (mean, SD, median, and peak height) at 1-month follow-up. Mirror ROIs were assessed for each patient for normal value. This was performed because physiological age-related variations are known,15 and these are important to consider when evaluating MTR in pathological states. For each patient, this normal contralateral mirror region was used as a control ROI for every comparison (CORE, IG, RDA, RPA).
To minimize errors related to imprecise coregistration and contouring,16 MTR measurements were performed when CORE volume was >1 cm3 and when IG, RPA, and RDA volumes were >2 cm3.
MTR values were thresholded at 15% to minimize partial volume averaging with cerebrospinal fluid that could lead to underestimate mean and median values.17

Statistical Analysis

Statistical analyses were performed using SAS (version 9.1.3). Main characteristics of patients, MRI volumes, and MTR values were described using mean, SD, and range. MTR parameters for each patient (mean and SD) were calculated from pixels (MTR values) distribution within each ROI. Mean MTR values of each ROI (CORE, IG, RPA, and RDA) were compared with that of mirror ROI. Because of nonindependence of data and small samples sizes, comparisons were assessed by a nonparametric Wilcoxon test using intra-individual differences in MTR parameters between each ROI and the normal contralateral ROI defined in each patient. Intergroup comparisons of MTR value between ROIs used either a nonparametric Wilcoxon test when measurements were taken from 2 different samples that were independent or a linear mixed model when they were not. P<0.05 was considered as a statistically significant difference. Spatial heterogeneity was studied using MTR SD in each ROI as an indicator of MTR values dispersion.
In a last step we looked for a relationship between the severity of initial insult and the 1-month follow-up MTR. We performed a Spearman correlation of the mean relative TTP delay or mean apparent diffusion coefficient (ADC) at the early stage, and the mean MTR at the chronic stage.

Results

Of the 30 subjects included, 11 were men and 19 women. They had a mean age of 61 years (SD,14; range, 23 to 79 years). For patients with delay data accurate to within the hour, MRI.1 was performed with a mean delay of 6.4 hours after the occurrence of stroke symptom (SD, 2.8; range, 2 to 11 hours; n=28). Two patients included within study had insufficiently accurate delay data but it was inferior to 12 hours. The mean NIHSS at admission was 8.4 (SD, 5.0; range, 4 to 20; n=29). Three patients underwent thrombolysis while the remaining received a anti-aggregation treatment. MRI.2 was obtained within a range of 30 to 44 days (mean, 36.0; SD, 4.4) and mean Barthel and Rankin scale were, respectively, 94/100 (range, 20 to 100; n=20) and 1/5 (range, 0 to 5; n=20).
Among the 16 patients who were included within 6 hours of stroke onset, 3 of them had a lesion decrease (including 2 patients who received TPA), 9 patients had a stable lesion (1 of them received TPA and had no visible lesion), and 4 had an infarct growth. Among the 14 patients who were included between 6 and 12 hours after stroke onset, 4 of them had a lesion decreased, 3 had a stable lesion, and 7 had an infarct growth.

Volumes

The mean CORE volume was 23.1 cm3 (SD, 39.6; n=30). For 25 patients this volume was >1 cm3 and for 5 it was <1 cm3 impeding MTR measurement. One patient had no visible lesion on DWI_MRI.1 and on FLAIR_MRI.2 but was included in our study because that patient was seen 2 hours and 30 minutes after stroke onset of left hemiplegia and hemianesthesia, and presented a middle cerebral artery occlusion with a large hypoperfusion. The patient received thrombolytic treatment and fully recovered.
The mean final infarct volume on FLAIR_MRI.2 was 25.3 cm3 (SD, 38.7; n=30). Comparing CORE and FLAIR_MRI.2 volumes showed: an infarct volume growth in 11 patients (mean, 11.8 cm3 [SD, 11.0] ie, IG); an infarct volume decrease in 7 patients (mean, 9.3 cm3 [SD, 6.0] ie, RDA); no significant volume change in the remaining 12 patients (−2 cm3<volume<2 cm3).
An area of prolonged TTP was observed in 25 patients with a mean volume of 56.2 cm3 (SD, 44.0). For 19 patients this volume (mean, 60.0 cm3; SD, 35.4) was significantly larger than the final infarct volume on FLAIR, allowing the calculation of RPA (mean, 35.7 cm3; SD, 22.2).

Repartition of MTR Parameters in the Different ROIs

The mean MTR in the contralateral, symmetric, normal-appearing parenchyma was 49.8% (SD, 1.9). We found a significant MTR decrease within all these ROIs compared with the symmetric contralateral hemisphere (Table). We found a continuum in mean MTR value repartition (Figure 2). Mean CORE value was the lowest, significantly different from IG and RDA (P=0.039 and P=0.0289, respectively). IG and RDA had similar degree of MTR decrease (P=0.85), and MTR measured in RDA was significantly lower than MTR measured in RPA (P=0.0154). In each ROI, mean MTR is calculated from all pixels within the ROI that are normally distributed around this mean with an individual SD. Individual standard deviation in each ROI is an indicator of MTR value dispersion and thus of the spatial homogeneity or heterogeneity. The mean of individual SD was 0.77% (n=30) in normal region, 0.99% (n=19) in RPA, and 1.75% (n=7) in RDA.
Table. Repartition of Mean MTR Values in the Different ROIs
 MTR%P*
Stroke Side, Mean (SD)Contralateral Side, Mean (SD)
*A nonparametric test (Wilcoxon test) was used to compare MTR mean values in the different ROIs to the mirror ROIs.
P<0.05 was considered as a statistically significant difference.
Mirror ROI (n=30)49.8 (1.9)
CORE ROI (n=25)40.9 (5.2)49.8 (1.8)<0.0001
IG ROI (n=11)43.1 (2.0)49.1 (1.6)0.0010
RDA ROI (n=7)43.2 (2.8)49.7 (2.4)0.0156
RPA ROI (n=19)45.2 (2.5)49.4 (2.0)<0.0001
Figure 2. Repartition of mean MTR values in the different ROIs. The cross inside the box represents the mean. Middle bar is the median. Upper and lower extremities of the box are first and third quartiles, respectively. Maximum and minimum values are represented by extreme lines.
Analysis of initial TTP delay and follow-up MTR value revealed a negative correlation (r=−0.29 in RDA and −0.04 in RPA), whereas there was a positive correlation between initial ADC and follow-up MTR (r=0.4 in the 4 regions). However, these correlations were weak.

Discussion

The ischemic penumbra has become one of the main targets of the thrombolytics and neuroprotective drugs in recent years. The volume of this tissue at-risk that escaped from infarction according to the 1-month FLAIR sequence has become a criterion for the evaluation of the efficacy of these treatments. This study demonstrated the presence of microstructural brain damage inside this area as suggested by low MTR measured in the areas of “reversible perfusion and diffusion abnormalities” (RPA and RDA) 30 to 45 days after stroke onset.
MT is a very robust sequence much more specific and sensitive to macromolecular loss than conventional sequences. It consists of applying an off-resonance radio frequency pulse that saturates, immobilizes, or restricts macromolecular protons. This saturation is transferred to the protons of mobile free water. The percentage reduction in the signal when the saturation is applied (ie, MTR) is thus proportional to the bound protons and depends on the density and nature of the macromolecules in a given tissue.10 High degrees of correlation have been found between MTR values and histopathological findings of myelin loss or axon destruction.13 Furthermore, this technique can depict abnormalities that are not visible on conventional images, so-called normal-appearing white or gray matter12 and is thus very useful to depict subtle damage.
Low MTR values were previously reported in the CORE of cerebral infarct18,19 with a decrease starting ≈7 days after stroke onset.18 It is related to the progressive loss of protein and fluid with clearing of necrotic debris that begins 5 to 7 days after the onset, after the initial cellular infiltration (lymphocyte, monocyte).19 Our results confirmed very low MTR values at one month in the CORE volumes indicating that MTR is a good marker of microstructural damage related to stroke insult. To our knowledge this has not been studied in the ischemic penumbra.
Therefore, regarding the main objective of this study that is to determine whether salvaged penumbra is fully reversible, the average MTR at 1 month is of particular interest in the 2 remaining volumes: RPA and RDA. In these regions that seem normalized according to the 1-month follow-up FLAIR, MTR values were significantly lower than in normal ROIs. Such abnormal MTR in normal-appearing white matter has already been reported in ischemic pathology, but in particular cases of patients with chronic hypoperfusion attributable to severe stenosis of the internal carotid artery,20 a clinical situation very different from acute stroke. Our results suggest a decrease of cellular content with potential neuronal loss despite normal appearance on FLAIR-weighted images. This can be put together with many histological observations performed on animal models.21–25 Garcia et al21 described lesions characterized by selective neuronal necrosis and various glial responses interpreted as incomplete infarction after arterial occlusions of short duration, entirely different from the pan necrosis/cavitation typical of an infarction. These rat models demonstrated that histological changes including neuronal necrosis were not completely detectable with conventional MRI sequence.25 As an example, after 10 minutes of transient focal ischemia, selective neuronal necrosis could reach 28% of the neurons with T2 remaining normal.23
For humans, such partial damage has been observed using specific radiotracer. Nakagawara et al26 reported a mild but significant reduction of iomazenil binding (SPECT radioligand for the mapping of cortical neuronal integrity in vivo) in cortical areas exhibiting hypoperfusion on acute stage, but no evident infarct on structural imaging by MRI. Recently, Saur et al27combined data of MRI and SPECT and also found a decrease of iomazenil cortical binding in ROIs equivalent to our RPA ROIs. We found that MTR is an attractive way to obtain the same type of information. Until now this additional information compared with conventional MRI needed a SPECT examination that implies a long duration of each scan, a spatial resolution less optimal than that of MRI, an exposure to ionizing radiation, and provided information concerning only cortical binding.
Delayed neuronal death could be caused by acute hypoperfusion but also reperfusion itself (so-called reperfusion injury28), as well as inflammatory process, especially microglia activation. We found that MTR in RDA was lower than in RPA. This can be interpreted as an indirect link between the severity of initial insult and later damage given that ADC reduction had been shown to be closely related to reduced energy metabolism, whereas TTP can overestimated severe cerebral blood flow decrease. Unfortunately, we could not know when patients were recanalyzed, a point that can explain why correlation between early TTP and later MTR was weak and not statistically significant, as well as between early ADC and later MTR.
We observed a continuum in MTR decrease from the periphery to the center but without difference between MTR values measured in IG (hyperintense on FLAIR images) and RDA (normal-appearing on FLAIR images). Histopathologic substratum that could explain these radiological appearances in IG and RDA is only speculative. We can think that in RDA there is only a water shift from intracellular to extracellular compartments without total water content increase. That is to say that water shifts to intracellular at the acute phase is responsible for diffusion restriction. It could go back to extracellular compartments in relation with diffusion normalization and coexists with partial neuronal death that would explain MTR decrease. In the case of IG, infarction evolution is probably more usual. FLAIR hypersignal could be caused by cystic changes in the damaged tissue but also to gliosis that can be important at the periphery and also results in prolongation of T1 and T2 relaxation times. This could lead to difficult and intricate modifications because we can speculate that neuronal death that would lead to MTR decrease could be underestimated because of astrocyte proliferation. Further experiments including histological correlations on animal models could help to go farther in the interpretation.
Any detrimental effect of these potential selective neuronal losses on neurological outcome/recovery remains poorly understood. Occasional persistence of dysphasia or hemi-neglect has been reported, despite apparently isolated striatocapsular infarct, which could be explained by a greater extension of selective neuronal loss.27,29 Two of the 30 patients presented an early cortical hypoperfusion with final infarct limited to subcortical structure associated with moderate but persistent signs of aphasia. Nevertheless, such anatomo-clinical correlations are always difficult given that interruption of networks implicated in the language can by itself lead to symptoms quite similar to those observed with cortical lesion and given the potential role of striatum in language.30 Although clinical outcome remains the major criterion of treatment efficacy in trial design for acute ischemic stroke, radiographic measurements are also a major category of end point assessment. Because MTR is easy to perform, reproducible, and is a surrogate marker of macromolecular content, it could be an attractive imaging marker in conjunction with other parameters such as infarct size or recanalization.
In such studies, several sources of potential bias should be avoided. First, in the study presented here, follow-up MRI was performed 30 to 45 days after stroke onset and atrophy seen in some cases could contribute to underestimate final infarct size. This was taken into account even if a little contribution of such shrinking phenomenon cannot be excluded. In the same way, edema at early stage could contribute to overestimate CORE volume especially after >6 hours from stroke onset. This was difficult to correct and could lead to increase RDA volume but would not drastically change the conclusion because if systematic correction could be applied, this potentially “false” RDA (with MTR decrease) would be part of RPA and would participate to RPA mean MTR decrease. Second, MTR decrease had more significance if it concerned a large part of the ROI and not only a small ring near to abnormalities already seen with FLAIR images, and it should be monitored by histogram dispersion. Third, other sequences could have been used instead of FLAIR to determine the size of the infarct at MRI.2. On the same group of patients we have compared the size of the infarct between DWI MRI.2 and FLAIR MRI.2. The final infarct size on DWI was smaller than on FLAIR images. This resulted in larger RPA and RDA with even a lower MTR in the salvaged penumbra.
This study indicates that partial damage may occur in tissues that seem to escape infarction according to conventional MRI sequences and shows in vivo definitive structural abnormalities in the reperfused penumbra. This can be considered as a further graduation between complete infarction and complete tissue salvage. Applied in therapeutic trials, MTR may bring additional information to the current T2 or FLAIR protocols and help to evaluate drugs that have objective to reduce brain tissue damage.

Acknowledgments

The authors thank Dr V. Sesay from the department of Neuroradiology at the University Hospital of Bordeaux, France, who supervised the VIRAGE database.
Source of Funding
VIRAGE was part of an approved national Research and Clinical Hospital Project funded in 2003 by a public national grant.
Disclosures
None.

References

1.
Kidwell CS, Alger JR, Saver JL. Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke. 2003; 34: 2729–2735.
2.
Albers GW. Expanding the window for thrombolytic therapy in acute stroke: the potential role of acute mri for patient selection. Stroke. 1999; 30: 2230–2237.
3.
Neumann-Haefelin T, Wittsack HJ, Wenserski F, Siebler M, Seitz RJ, Modder U, Freund HJ. Diffusion- and perfusion-weighted MRI. The DWI/PWI mismatch region in acute stroke. Stroke. 1999; 30: 1591–1597.
4.
Schlaug G, Benfield A, Baird AE, Siewert B, Lovblad KO, Parker RA, Edelman RR, Warach S. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology. 1999; 53: 1528–1537.
5.
Fiehler J, Foth M, Kucinski T, Knab R, von Bezold M, Weiller C, Zeumer H, Rother J. Severe ADC decreases do not predict irreversible tissue damage in humans. Stroke. 2002; 33: 79–86.
6.
Heiss WD, Sobesky J, Smekal U, Kracht LW, Lehnhardt FG, Thiel A, Jacobs AH, Lackner K. Probability of cortical infarction predicted by flumazenil binding and diffusion-weighted imaging signal intensity: a comparative positron emission tomography/magnetic resonance imaging study in early ischemic stroke. Stroke. 2004; 35: 1892–1898.
7.
Fiehler J, Knudsen K, Kucinski T, Kidwell CS, Alger JR, Thomalla G, Eckert B, Wittkugel O, Weiller C, Zeumer H, Rother J. Predictors of apparent diffusion coefficient normalization in stroke patients. Stroke. 2004; 35: 514–519.
8.
Kidwell CS, Saver JL, Mattiello J, Starkman S, Vinuela F, Duckwiler G, Gobin YP, Jahan R, Vespa P, Kalafut M, Alger JR. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol. 2000; 47: 462–469.
9.
Lecouvet FE, Duprez TP, Raymackers JM, Peeters A, Cosnard G. Resolution of early diffusion-weighted and flair MRI abnormalities in a patient with TIA. Neurology. 1999; 52: 1085–1087.
10.
Tofts P, Steens S, Van Buchem M. MT: magnetization transfer. In: Tofts P, ed. Quantitative MRI of the Brain: Measuring Changes Caused by Disease. Cichester: Wiley; 2003: 257–298.
11.
Fralix TA, Ceckler TL, Wolff SD, Simon SA, Balaban RS. Lipid bilayer and water proton magnetization transfer: effect of cholesterol. Magn Reson Med. 1991; 18: 214–223.
12.
Dousset V, Grossman RI, Ramer KN, Schnall MD, Young LH, Gonzalez-Scarano F, Lavi E, Cohen JA. Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology. 1992; 182: 483–491.
13.
van Waesberghe JH, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, Lycklama a Nijeholt GJ, van der Valk P, Polman CH, Thompson AJ, Barkhof F. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol. 1999; 46: 747–754.
14.
Sobesky J, Zaro Weber O, Lehnhardt FG, Hesselmann V, Thiel A, Dohmen C, Jacobs A, Neveling M, Heiss WD. Which time-to-peak threshold best identifies penumbral flow? A comparison of perfusion-weighted magnetic resonance imaging and positron emission tomography in acute ischemic stroke. Stroke. 2004; 35: 2843–2847.
15.
Ge Y, Grossman RI, Babb JS, Rabin ML, Mannon LJ, Kolson DL. Age-related total gray matter and white matter changes in normal adult brain. Part II: quantitative magnetization transfer ratio histogram analysis. AJNR Am J Neuroradiol. 2002; 23: 1334–1341.
16.
Oppenheim C, Grandin C, Samson Y, Smith A, Duprez T, Marsault C, Cosnard G. Is there an apparent diffusion coefficient threshold in predicting tissue viability in hyperacute stroke? Stroke. 2001; 32: 2486–2491.
17.
Iannucci G, Dichgans M, Rovaris M, Bruning R, Gasser T, Giacomotti L, Yousry TA, Filippi M. Correlations between clinical findings and magnetization transfer imaging metrics of tissue damage in individuals with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke. 2001; 32: 643–648.
18.
Kovacs Z, Ikezaki K, Takahashi M, Kawai J, Fukui M. A chronological evaluation of experimental brain infarct by diffusion-mapping and magnetization transfer contrast imaging. Acta Neurochir Suppl. 1997; 70: 43–45.
19.
Prager JM, Rosenblum JD, Huddle DC, Diamond CK, Metz CE. The magnetization transfer effect in cerebral infarction. AJNR Am J Neuroradiol. 1994; 15: 1497–1500.
20.
Kado H, Kimura H, Tsuchida T, Yonekura Y, Tokime T, Tokuriki Y, Itoh H. Abnormal magnetization transfer ratios in normal-appearing white matter on conventional mr images of patients with occlusive cerebrovascular disease. AJNR Am J Neuroradiol. 2001; 22: 922–927.
21.
Garcia JH, Liu KF, Ye ZR, Gutierrez JA Incomplete infarct and delayed neuronal death after transient middle cerebral artery occlusion in rats. Stroke. 1997; 28: 2303–2310.
22.
Miyasaka N, Kuroiwa T, Zhao FY, Nagaoka T, Akimoto H, Yamada I, Kubota T, Aso T. Cerebral ischemic hypoxia: discrepancy between apparent diffusion coefficients and histologic changes in rats. Radiology. 2000; 215: 199–204.
23.
Li F, Liu KF, Silva MD, Omae T, Sotak CH, Fenstermacher JD, Fisher M, Hsu CY, Lin W. Transient and permanent resolution of ischemic lesions on diffusion-weighted imaging after brief periods of focal ischemia in rats: correlation with histopathology. Stroke. 2000; 31: 946–954.
24.
Ringer TM, Neumann-Haefelin T, Sobel RA, Moseley ME, Yenari MA. Reversal of early diffusion-weighted magnetic resonance imaging abnormalities does not necessarily reflect tissue salvage in experimental cerebral ischemia. Stroke. 2001; 32: 2362–2369.
25.
Neumann-Haefelin T, Kastrup A, de Crespigny A, Yenari MA, Ringer T, Sun GH, Moseley ME. Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood-brain barrier damage, and edema formation. Stroke. 2000; 31: 1965–1972;discussion 1972–1963.
26.
Nakagawara J, Sperling B, Lassen NA. Incomplete brain infarction of reperfused cortex may be quantitated with iomazenil. Stroke. 1997; 28: 124–132.
27.
Saur D, Buchert R, Knab R, Weiller C, Rother J. Iomazenil-single-photon emission computed tomography reveals selective neuronal loss in magnetic resonance-defined mismatch areas. Stroke. 2006; 37: 2713–2719.
28.
Schaller B, Graf R. Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy. J Cereb Blood Flow Metab. 2004; 24: 351–371.
29.
Weiller C, Willmes K, Reiche W, Thron A, Isensee C, Buell U, Ringelstein EB. The case of aphasia or neglect after striatocapsular infarction. Brain. 1993; 116 (Pt 6): 1509–1525.
30.
Ullman MT. A neurocognitive perspective on language: the declarative/procedural model. Nat Rev Neurosci. 2001; 2: 717–726.

eLetters(0)

eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.

Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.

Information & Authors

Information

Published In

Go to Stroke
Go to Stroke

On the cover: The illustration is taken from an article in this issue, "Novel Mouse Model of Monocular Amaurosis Fugax" by Lelong et al (Stroke. 2007;38:3237–3244.)

Versions

You are viewing the most recent version of this article.

History

Received: 30 January 2007
Revision received: 26 May 2007
Accepted: 29 May 2007
Published online: 25 October 2007
Published in print: 1 December 2007

Permissions

Request permissions for this article.

Keywords

  1. acute cerebral infarction
  2. incomplete infarct
  3. ischemic penumbra
  4. magnetization transfer imaging

Authors

Affiliations

Thomas Tourdias, MD
From the CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique (T.T., V.D., E.P., P.M.), Service de Neurologie A (I.S., F.R., J.M.O.), Unité de soutien méthodologique à la recherche clinique et épidémiologique (J.A., G.C.), Departement de Pharmacologie (P.R.), Bordeaux, France; Société Theralys, Diagnostic and Therapeutic Image Analysis in Clinical Trials (C.P.), Bioparc, Lyon France.
Vincent Dousset, MD, PhD
From the CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique (T.T., V.D., E.P., P.M.), Service de Neurologie A (I.S., F.R., J.M.O.), Unité de soutien méthodologique à la recherche clinique et épidémiologique (J.A., G.C.), Departement de Pharmacologie (P.R.), Bordeaux, France; Société Theralys, Diagnostic and Therapeutic Image Analysis in Clinical Trials (C.P.), Bioparc, Lyon France.
Igor Sibon, MD, PhD
From the CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique (T.T., V.D., E.P., P.M.), Service de Neurologie A (I.S., F.R., J.M.O.), Unité de soutien méthodologique à la recherche clinique et épidémiologique (J.A., G.C.), Departement de Pharmacologie (P.R.), Bordeaux, France; Société Theralys, Diagnostic and Therapeutic Image Analysis in Clinical Trials (C.P.), Bioparc, Lyon France.
Eric Pele, MD
From the CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique (T.T., V.D., E.P., P.M.), Service de Neurologie A (I.S., F.R., J.M.O.), Unité de soutien méthodologique à la recherche clinique et épidémiologique (J.A., G.C.), Departement de Pharmacologie (P.R.), Bordeaux, France; Société Theralys, Diagnostic and Therapeutic Image Analysis in Clinical Trials (C.P.), Bioparc, Lyon France.
Patrice Menegon, MD
From the CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique (T.T., V.D., E.P., P.M.), Service de Neurologie A (I.S., F.R., J.M.O.), Unité de soutien méthodologique à la recherche clinique et épidémiologique (J.A., G.C.), Departement de Pharmacologie (P.R.), Bordeaux, France; Société Theralys, Diagnostic and Therapeutic Image Analysis in Clinical Trials (C.P.), Bioparc, Lyon France.
Julien Asselineau, MD
From the CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique (T.T., V.D., E.P., P.M.), Service de Neurologie A (I.S., F.R., J.M.O.), Unité de soutien méthodologique à la recherche clinique et épidémiologique (J.A., G.C.), Departement de Pharmacologie (P.R.), Bordeaux, France; Société Theralys, Diagnostic and Therapeutic Image Analysis in Clinical Trials (C.P.), Bioparc, Lyon France.
Chahin Pachai, MD, PhD
From the CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique (T.T., V.D., E.P., P.M.), Service de Neurologie A (I.S., F.R., J.M.O.), Unité de soutien méthodologique à la recherche clinique et épidémiologique (J.A., G.C.), Departement de Pharmacologie (P.R.), Bordeaux, France; Société Theralys, Diagnostic and Therapeutic Image Analysis in Clinical Trials (C.P.), Bioparc, Lyon France.
François Rouanet, MD
From the CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique (T.T., V.D., E.P., P.M.), Service de Neurologie A (I.S., F.R., J.M.O.), Unité de soutien méthodologique à la recherche clinique et épidémiologique (J.A., G.C.), Departement de Pharmacologie (P.R.), Bordeaux, France; Société Theralys, Diagnostic and Therapeutic Image Analysis in Clinical Trials (C.P.), Bioparc, Lyon France.
Philip Robinson, PhD
From the CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique (T.T., V.D., E.P., P.M.), Service de Neurologie A (I.S., F.R., J.M.O.), Unité de soutien méthodologique à la recherche clinique et épidémiologique (J.A., G.C.), Departement de Pharmacologie (P.R.), Bordeaux, France; Société Theralys, Diagnostic and Therapeutic Image Analysis in Clinical Trials (C.P.), Bioparc, Lyon France.
Geneviève Chene, MD
From the CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique (T.T., V.D., E.P., P.M.), Service de Neurologie A (I.S., F.R., J.M.O.), Unité de soutien méthodologique à la recherche clinique et épidémiologique (J.A., G.C.), Departement de Pharmacologie (P.R.), Bordeaux, France; Société Theralys, Diagnostic and Therapeutic Image Analysis in Clinical Trials (C.P.), Bioparc, Lyon France.
Jean Marc Orgogozo, MD
From the CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique (T.T., V.D., E.P., P.M.), Service de Neurologie A (I.S., F.R., J.M.O.), Unité de soutien méthodologique à la recherche clinique et épidémiologique (J.A., G.C.), Departement de Pharmacologie (P.R.), Bordeaux, France; Société Theralys, Diagnostic and Therapeutic Image Analysis in Clinical Trials (C.P.), Bioparc, Lyon France.

Notes

Correspondence to Vincent Dousset, MD, PhD, CHU de Bordeaux, Université Victor Segalen Bordeaux 2, Service de Neuroradiologie diagnostique et thérapeutique, Place Amélie Raba-Léon, Bordeaux, France 33000. E-mail [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

  1. Early penumbral FLAIR changes predict tissue fate in patients with large vessel occlusions, International Journal of Stroke, (2024).https://doi.org/10.1177/17474930241289235
    Crossref
  2. Reduced Severity of Tissue Injury Within the Infarct May Partially Mediate the Benefit of Reperfusion in Ischemic Stroke, Stroke, 53, 6, (1915-1923), (2022)./doi/10.1161/STROKEAHA.121.036670
    Abstract
  3. High glycemic variability: An underestimated determinant of stroke functional outcome following large vessel occlusion, Revue Neurologique, 178, 7, (732-740), (2022).https://doi.org/10.1016/j.neurol.2021.12.010
    Crossref
  4. Quantitative chemical exchange saturation transfer imaging of nuclear overhauser effects in acute ischemic stroke, Magnetic Resonance in Medicine, 88, 1, (341-356), (2022).https://doi.org/10.1002/mrm.29187
    Crossref
  5. Reversible Edema in the Penumbra Correlates With Severity of Hypoperfusion, Stroke, 52, 7, (2338-2346), (2021)./doi/10.1161/STROKEAHA.120.033071
    Abstract
  6. Imaging After Thrombolysis and Thrombectomy: Rationale, Modalities and Management Implications, Current Neurology and Neuroscience Reports, 19, 8, (2019).https://doi.org/10.1007/s11910-019-0970-7
    Crossref
  7. The new insights into human brain imaging after stroke, Journal of Neuroscience Research, 100, 5, (1171-1181), (2019).https://doi.org/10.1002/jnr.24525
    Crossref
  8. Quantitative assessment of demyelination in ischemic stroke in vivo using macromolecular proton fraction mapping, Journal of Cerebral Blood Flow & Metabolism, 38, 5, (919-931), (2018).https://doi.org/10.1177/0271678X18755203
    Crossref
  9. Evolution of Cerebral Ischemia Assessed by Amide Proton Transfer-Weighted MRI, Frontiers in Neurology, 8, (2017).https://doi.org/10.3389/fneur.2017.00067
    Crossref
  10. A Longitudinal Magnetization Transfer Imaging Evaluation of Brain Injury in a Macaque Model of NeuroAIDS, AIDS Research and Human Retroviruses, 31, 3, (335-341), (2015).https://doi.org/10.1089/aid.2014.0166
    Crossref
  11. See more
Loading...

View Options

View options

PDF and All Supplements

Download PDF and All Supplements

PDF/EPUB

View PDF/EPUB
Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to access the full text.

Purchase access to this article for 24 hours

Magnetization Transfer Imaging Shows Tissue Abnormalities in the Reversible Penumbra
Stroke
  • Vol. 38
  • No. 12

Purchase access to this journal for 24 hours

Stroke
  • Vol. 38
  • No. 12
Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

Figures

Tables

Media

Share

Share

Share article link

Share

Comment Response